

Russian Federation

| High TB burden | High HIV burden | High MDR-TB burden |

Tuberculosis profile

Population 2013

143 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	17 (17–18)	12 (12–13)
Mortality (HIV+TB only)	1.4 (1–1.9)	0.98 (0.7–1.3)
Prevalence (includes HIV+TB)	160 (74–290)	114 (51–201)
Incidence (includes HIV+TB)	130 (120–140)	89 (82–100)
Incidence (HIV+TB only)	7.9 (6.9–9.1)	5.5 (4.8–6.4)
Case detection, all forms (%)	83 (74–91)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	19 (14–25)	49 (40–59)
MDR-TB cases among notified pulmonary TB cases	16 000 (11 000–20 000)	25 000 (20 000–30 000)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	37 779	7 866
Pulmonary, clinically diagnosed	43 859	7 194
Extrapulmonary	8 789	566

Total new and relapse	106 053
Previously treated, excluding relapses	36 480
Total cases notified	142 533

Among 90 427 new cases:

3 298 (4%) cases aged under 15 years; male:female ratio: 2.2

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	31 677 (84%)	12 066 (23%)	43 743
Laboratory-confirmed RR-/MDR-TB cases			13 521
Patients started on MDR-TB treatment			20 372

TB/HIV 2013	Number	(%)
TB patients with known HIV status	69 724	
HIV-positive TB patients	4 990	
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	69
Previously treated cases, excluding relapse, registered in 2012	37
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	37
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	3.7
Culture (per 5 million population)	11.6
Drug susceptibility testing (per 5 million population)	7.6
Sites performing Xpert MTB/RIF	72
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	1 827
% Funded domestically	100%
% Funded internationally	
% Unfunded	0%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded